about
Comparison of routine bench and molecular diagnostic methods in identification of Burkholderia pseudomalleiComparison of automated and nonautomated systems for identification of Burkholderia pseudomalleiPathogens penetrating the central nervous system: infection pathways and the cellular and molecular mechanisms of invasionPrimary amoebic meningoencephalitis in North Queensland: the paediatric experience.The double burden: a new-age pandemic meets an ancient infection.Late Onset Neonatal Sepsis - A 10 Year Review from North Queensland, Australia.Q fever in an endemic region of North Queensland, Australia: A 10 year reviewSpatial analysis of melioidosis distribution in a suburban area.Brucellosis in northern AustraliaEvidence of Burkholderia pseudomallei-specific immunity in patient sera persistently nonreactive by the indirect hemagglutination assayA prospective study of melioidosis after environmental exposure of healthy participants to Burkholderia pseudomallei during a muddy endurance challenge.Cardiac myosin epitopes for monitoring progression of rheumatic fever.Diabetes: A Contributor to Tuberculosis in Tropical AustraliaMore parasitic myositis cases in humans in Australia, and the definition of genetic markers for the causative agents as a basis for molecular diagnosis.Genetic diversity of Burkholderia pseudomallei isolates in Australia.Mycobacterial soft tissue infections in North Queensland.Correction for Johnson et al., Complete Genome Sequences for 59 Burkholderia Isolates, Both Pathogenic and Near Neighbor.Q fever cases at a North Queensland centre during 1994-2006.Neurologic melioidosis.Clinical features that affect indirect-hemagglutination-assay responses to Burkholderia pseudomallei.Corynebacterium aquaticum septicaemia in a neutropenic patient.Clinical presentation of rheumatic fever in an endemic area.Challenges in the microbiological diagnosis and management of hVISA infections.Paediatric bacteraemias in tropical Australia.Epidemiological cut-off value of clinical isolates of Burkholderia pseudomallei from Northern Queensland to meropenem, ceftazidime, trimethoprim/sulfamethoxazole and doxycycline by the microbroth dilution method.Cryptococcosis-the impact of delay to diagnosis.Overrepresentation of Diabetes in Soft Tissue Nontuberculous Mycobacterial Infections.ELISA and immuno-polymerase chain reaction assays for the sensitive detection of melioidosis.Genetic analysis of Giardia and Cryptosporidium from people in Northern Australia using PCR-based tools.Survival, sublethal injury, and recovery of environmental Burkholderia pseudomallei in soil subjected to desiccation.A comparison of antibiotic susceptibility testing methods for cotrimoxazole with Burkholderia pseudomallei.Bacteraemias in tropical Australia: changing trends over a 10-year period.G-CSF immunotherapy for treatment of acute disseminated murine melioidosis.Rapid diagnostics for melioidosis: a comparative study of a novel lateral flow antigen detection assay.Combination antimicrobial therapy of acute Burkholderia pseudomallei infection in a mouse model.Evaluation of the Remel RapID NF plus rapid biochemical method for identification of Burkholderia pseudomallei.Acute Q fever in northern Queensland: variation in incidence related to rainfall and geographical location.Neuromelioidosis: Craniospinal MRI Findings in Burkholderia pseudomallei Infection.Comparison of the susceptibilities of Burkholderia pseudomallei to meropenem and ceftazidime by conventional and intracellular methodsEvaluation of a commercially available synthetic RNA lipid enveloped control molecule.
P50
Q24644427-59EF6EEE-8084-46A6-9BB5-DB374BE2CBCCQ24675904-8FA291E1-ECE5-4049-951F-3061037B27C0Q27027234-0BB251A3-CFDD-46A0-BDCE-E989433E8F66Q30245037-941098CB-FA4D-4243-93C5-EBA109BE7549Q30366075-3794DF18-4811-48CD-ADD9-2ED1DEEB8566Q33439148-E6A76BB3-BB27-4023-86E3-27F513794909Q33753485-42535A95-F5A0-4018-90DB-D7D47F12C4C9Q34094090-9D3E47E6-7DB8-4C2E-AF10-7EA3E0CC0647Q34160153-38E211CE-8C71-40FF-BED5-042961391736Q35138764-A4A331AC-4AE0-4250-88F6-BFF8097872B8Q35272665-8C2E29EA-833F-4757-8495-243137ABB3F8Q35979263-572CC79F-1045-4FC0-B23C-BC4F4943EB1EQ36026279-987A0149-EA76-435B-ABD2-95596761EC62Q36054783-AAF6F433-AA2B-489B-B406-F4C26FD75814Q36423802-138E4508-9BAF-4423-B6DC-D5F2EDBC4185Q36819804-DA3AF3EB-C45D-4A75-ACC0-217D1ABE9D9FQ36826130-AF464589-6587-4C18-AD11-7AF6F988A578Q36917072-F2D29FA6-7198-4EC4-B8F4-CA75C599BB0CQ37166158-0B29AD44-EBE1-42C4-8B1E-F72DFD7B3584Q37213889-092E4CEC-50D3-4701-B3E8-ABACF55C8461Q37268941-27A52BC0-4E8D-4DE8-8440-E71EF349B1F5Q37625546-16230155-08CC-4721-A483-025EC648FF39Q37870662-618F8E9F-28CB-44DE-BA32-92023E21A475Q38260312-C7919675-F4F3-49C0-B83C-396E31DC85DAQ38669297-BB203015-6861-4A23-9021-28A16D6DBB43Q38833003-F6C8C2FB-70E8-4392-97C0-E83489EDF3A8Q38921128-C61149B6-C65C-45DA-B36E-9CFFB764EEF7Q38952691-2193AD68-2E82-4FCD-86F4-D8B3BE01DAD4Q38969175-722DFBCC-1B5C-4754-B6D0-304CBEF92BD5Q39161201-BE2CF4F5-8789-48FB-B4A2-2EFEED925422Q39356268-96084C5A-9AAA-43B2-BB9E-D17B2AC7EB82Q39364698-ADE83631-C998-4491-81A5-88467084E2D7Q39365995-6FBD17E1-DE06-4A5F-8DB1-0F965247FC2CQ39402316-9E409720-F173-469D-9D58-121595BF4BEAQ39541205-AD3CF562-E5F4-42C6-A6B1-397BAB52BF1DQ40210378-D9EE2E82-FE1E-44EC-9047-2DF74E31A4E8Q40277988-848F0FE8-9F01-401C-8914-08369E039337Q40643688-7B129D42-DA80-426F-9D89-5FE823148DC9Q41269397-E0BC50AF-077A-4C5B-8DC0-8F5CE00613C6Q42178358-BBF8E3E9-4808-4705-88A0-38A768F420DC
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Robert Norton
@ast
Robert Norton
@en
Robert Norton
@es
Robert Norton
@nl
Robert Norton
@sl
type
label
Robert Norton
@ast
Robert Norton
@en
Robert Norton
@es
Robert Norton
@nl
Robert Norton
@sl
prefLabel
Robert Norton
@ast
Robert Norton
@en
Robert Norton
@es
Robert Norton
@nl
Robert Norton
@sl
P106
P1153
7202155528
P21
P31
P496
0000-0003-3948-9272